Page 12 - Laboratory Values News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Alexej Nawalny: Die Ära der Dissidenten
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Das bedeuten die Werte in deinem Blutbild
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
In kleinen Schritten zur E-Akte
aerztezeitung.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aerztezeitung.de Daily Mail and Mail on Sunday newspapers.
Arbeit mit Herz, Hand - und Abstand
mainpost.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mainpost.de Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
INDIANAPOLIS, April 8, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including extracorporeal membrane oxygenation (ECMO) or death by Day 28. Baricitinib-treated patients were 2.7 percent less likely than those receiving standard of care to progress to ventilation (non-invasive or mechanical) or death, a difference that was not statistically significant (odds ratio [OR]: 0.85; 95% CI 0.67, 1.08; p=0.1800).